Pasar al contenido principal

PAPEL DE LA CORTEZA INFRALIMBICA EN DEPRESION: CONECTIVIDAD FUNCIONAL Y DESARROLLO DE UN MODELO ANIMAL

SAF2012-35183

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2012
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Secretaría de Estado de Investigación, Desarrollo e Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Differential patterns of subcortical activity evoked by Glial GLT-1 blockade in prelimbic and infralimbic cortex: Relationship to antidepressant-like effects in rats

  • Gasull-Camos, Julia
  • Soto Montenegro, Mª Luisa
  • Casquero-Veiga, Marta
  • Desco Menéndez, Manuel
  • Artigas, Francesc
  • Castañe, Anna
Background: Glutamatergic neurotransmission has emerged as a novel target in antidepressant drug development, with a critical role of the ventral anterior cingulate cortex. We recently reported that blockade of the astrocytic glutamate transporter GLT-1 with dihydrokainic acid in infralimbic cortex (rodent equivalent of ventral anterior cingulate cortex), but not in the adjacent prelimbic cortex, evoked robust antidepressant-like effects through alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation and increased serotonin release. Methods: 2-deoxy-2-[F-18]-fluoro-D-glucose-positron emission tomography and computed tomography in 36 male Wistar rats microinfused bilaterally in prelimbic cortex or infralimbic cortex with dihydrokainic acid or vehicle. Results: Dihydrokainic acid microinfusion in infralimbic cortex and prelimbic cortex evoked dramatically different regional patterns of subcortical activity. In infralimbic cortex, dihydrokainic acid selectively affected midbrain areas, whereas in prelimbic cortex it affected the basal ganglia, the thalamus, and both superior and inferior colliculi. Conclusions: These results highlight the differential connectivity of infralimbic and prelimbic cortex with subcortical brain regions and support the involvement of infralimbic cortex-midbrain pathway in the antidepressant-like effects of dihydrokainic acid., This work was supported by Spanish Ministry of Economy and Competitiveness grants (SAF2012-35183, SAF2015-68346, ISCIII-FIS PI14/00860 and CPII14/00005, and BES2013-063241 J.GC.) cofinanced by European Regional Development Fund, Generalitat de Catalunya (2014-SGR798), Comunidad de Madrid (BRADE-CM S2013/ICE-2958), Mapfre foundation, Alicia Koplowitz Foundation (FAK16/01), and Centro de Investigación Biomédica en Red de Salud Mental.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder

  • Alvarez, Enric
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Artigas, Francesc|||0000-0002-5880-5720
Vortioxetine is a new multimodal action antidepressant with two types of action: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. It is an antagonist of the 5-HT3 and 5-HT7 receptors, a partial agonist of 5-HT1B, and an agonist of 5-HT1A. Its combined action on SERT and four subtypes of serotoninergic receptors increases the extracellular concentration of serotonin, dopamine, and noradrenaline. Twelve clinical trials have been carried out, nine of which had positive results versus placebo. When active comparators were included in the study design, no significant differences were found except in one study in which the efficacy of vortioxetine was superior to the comparator (agomelatine) in depression resistant to selective serotonin reuptake inhibitors (SSRI)/serotonin-norepinephrine reuptake inhibitors (SNRI) treatment. Tolerability studies indicate that the drug does not cause any important problems on blood tests, vital signs, or on electrocardiography. The lack of weight gain and induction of metabolic syndrome and the lack of significant changes in the QTc are especially important. The incidence rate of sexual dysfunction is low and similar to placebo in various trials. Similarly, cognitive function remains intact with vortioxetine.